N6022

Summary

N6022 (CHEMBL1738699) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including asthma and cystic fibrosis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 3
• Chemistry: 414.5 Da · C24H22N4O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1738699
Name	N6022
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	44623946
Molecular formula	C24H22N4O3
Molecular weight	414.5
InChIKey	YVPGZQLRPAGKLA-UHFFFAOYSA-N

SMILES: CC1=C(C=CC(=C1)C(=O)N)N2C(=CC=C2C3=CC=C(C=C3)N4C=CN=C4)CCC(=O)O

IUPAC name: 3-[1-(4-carbamoyl-2-methylphenyl)-5-(4-imidazol-1-ylphenyl)pyrrol-2-yl]propanoic acid

Also known as: N-6022, N6022

Patent coverage: 33 distinct patent families (117 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 110 (94%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Cytochrome P450 2C19, Alcohol dehydrogenase class-3.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 3 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ADH5	7.7	IC50	20	nM	CHEMBL_ACT_18732813
CYP2C19	6.11	IC50	770	nM	CHEMBL_ACT_6372488
CYP2C19	6.11	IC50	770	nM	CHEMBL_ACT_8039657

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
asthma	1	MONDO:0004979	MONDO:0004979
cystic fibrosis	1	MONDO:0009061	MONDO:0009061

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE1	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01147406	PHASE1	COMPLETED	Safety and Tolerability Study of N6022 in Healthy Subjects
NCT01339897	PHASE1	COMPLETED	A Safety Study Evaluating N6022 in Multiple-Ascending Doses in Healthy Subjects
NCT01746784	PHASE1	COMPLETED	Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).